 Taizo Nakano
Concepts (164)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Aplastic | 9 | 2024 | 36 | 2.230 |
Why?
| | Myelodysplastic Syndromes | 3 | 2021 | 129 | 1.420 |
Why?
| | Purpura, Thrombocytopenic, Idiopathic | 2 | 2024 | 14 | 1.160 |
Why?
| | Bone Marrow Diseases | 3 | 2023 | 19 | 1.080 |
Why?
| | Kasabach-Merritt Syndrome | 2 | 2023 | 7 | 1.000 |
Why?
| | Hematologic Diseases | 2 | 2023 | 60 | 1.000 |
Why?
| | Pancytopenia | 1 | 2023 | 8 | 0.840 |
Why?
| | Chylous Ascites | 1 | 2022 | 6 | 0.800 |
Why?
| | Chylothorax | 1 | 2022 | 16 | 0.800 |
Why?
| | Noonan Syndrome | 1 | 2022 | 17 | 0.770 |
Why?
| | Respiration Disorders | 1 | 2022 | 72 | 0.760 |
Why?
| | Leukemia, Myeloid, Acute | 3 | 2022 | 592 | 0.690 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2024 | 575 | 0.620 |
Why?
| | Child | 21 | 2024 | 20805 | 0.450 |
Why?
| | Decision Making | 1 | 2020 | 847 | 0.420 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 2 | 2024 | 28 | 0.380 |
Why?
| | Sialic Acids | 1 | 2011 | 9 | 0.380 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1262 | 0.370 |
Why?
| | Antineoplastic Agents | 1 | 2022 | 2042 | 0.360 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 278 | 0.310 |
Why?
| | Humans | 31 | 2024 | 128499 | 0.270 |
Why?
| | MDS1 and EVI1 Complex Locus Protein | 2 | 2023 | 6 | 0.260 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2011 | 1349 | 0.240 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 2 | 2023 | 131 | 0.240 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2024 | 26 | 0.230 |
Why?
| | Arthritis, Juvenile | 1 | 2024 | 53 | 0.220 |
Why?
| | Hemangioendothelioma | 1 | 2023 | 15 | 0.220 |
Why?
| | Vascular Neoplasms | 1 | 2023 | 17 | 0.220 |
Why?
| | Rheumatic Diseases | 1 | 2024 | 69 | 0.220 |
Why?
| | Hemangioma | 1 | 2023 | 43 | 0.210 |
Why?
| | Terminology as Topic | 1 | 2024 | 199 | 0.210 |
Why?
| | Sarcoma, Kaposi | 1 | 2023 | 76 | 0.210 |
Why?
| | Wnt Signaling Pathway | 1 | 2024 | 166 | 0.210 |
Why?
| | Proto-Oncogenes | 1 | 2022 | 29 | 0.200 |
Why?
| | Venous Thrombosis | 1 | 2024 | 176 | 0.200 |
Why?
| | Fanconi Anemia | 1 | 2022 | 10 | 0.200 |
Why?
| | Ascites | 1 | 2022 | 44 | 0.200 |
Why?
| | Syndrome | 1 | 2023 | 336 | 0.200 |
Why?
| | Exocrine Pancreatic Insufficiency | 1 | 2022 | 20 | 0.190 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2023 | 259 | 0.190 |
Why?
| | Child, Preschool | 11 | 2024 | 10487 | 0.190 |
Why?
| | Pyrimidinones | 1 | 2022 | 103 | 0.190 |
Why?
| | Drainage | 1 | 2022 | 165 | 0.190 |
Why?
| | Genetic Counseling | 1 | 2021 | 72 | 0.180 |
Why?
| | Bone Marrow Transplantation | 2 | 2020 | 269 | 0.180 |
Why?
| | Hepatitis | 1 | 2021 | 47 | 0.180 |
Why?
| | Pyridones | 1 | 2022 | 158 | 0.170 |
Why?
| | Disease Management | 1 | 2024 | 584 | 0.170 |
Why?
| | Infant | 10 | 2024 | 9001 | 0.160 |
Why?
| | Prognosis | 4 | 2020 | 3780 | 0.160 |
Why?
| | Immunosuppressive Agents | 2 | 2021 | 684 | 0.160 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 758 | 0.160 |
Why?
| | Antilymphocyte Serum | 1 | 2019 | 63 | 0.160 |
Why?
| | Hematopoietic System | 1 | 2018 | 8 | 0.160 |
Why?
| | Survival Rate | 2 | 2020 | 1871 | 0.150 |
Why?
| | Adolescent | 11 | 2024 | 20304 | 0.150 |
Why?
| | Zebrafish | 1 | 2023 | 464 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2020 | 180 | 0.150 |
Why?
| | Sclerotherapy | 1 | 2018 | 19 | 0.150 |
Why?
| | Young Adult | 9 | 2024 | 12349 | 0.150 |
Why?
| | Cyclosporine | 1 | 2019 | 171 | 0.150 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2018 | 36 | 0.150 |
Why?
| | Lymphatic Abnormalities | 1 | 2018 | 19 | 0.150 |
Why?
| | Metformin | 1 | 2022 | 314 | 0.150 |
Why?
| | Doxycycline | 1 | 2018 | 57 | 0.150 |
Why?
| | Transcription Factors | 2 | 2023 | 1635 | 0.150 |
Why?
| | Retrospective Studies | 8 | 2024 | 14472 | 0.140 |
Why?
| | Genome-Wide Association Study | 1 | 2024 | 1332 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1357 | 0.140 |
Why?
| | Secondary Prevention | 1 | 2018 | 219 | 0.140 |
Why?
| | Neoplasms | 1 | 2011 | 2463 | 0.130 |
Why?
| | Liver Transplantation | 1 | 2024 | 800 | 0.130 |
Why?
| | Spleen | 1 | 2018 | 509 | 0.130 |
Why?
| | Patient Selection | 1 | 2020 | 661 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 2023 | 820 | 0.130 |
Why?
| | Phenotype | 1 | 2023 | 3051 | 0.110 |
Why?
| | Adult | 9 | 2024 | 35302 | 0.100 |
Why?
| | Hyperbilirubinemia | 1 | 2012 | 11 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 702 | 0.090 |
Why?
| | Sialyltransferases | 1 | 2011 | 13 | 0.090 |
Why?
| | Induction Chemotherapy | 1 | 2012 | 70 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2024 | 10162 | 0.090 |
Why?
| | Anemia, Hemolytic, Congenital | 1 | 2011 | 1 | 0.090 |
Why?
| | Porphyria, Erythropoietic | 1 | 2011 | 2 | 0.090 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 87 | 0.090 |
Why?
| | Female | 12 | 2024 | 68268 | 0.090 |
Why?
| | Inflammation | 1 | 2022 | 2666 | 0.090 |
Why?
| | Pancreatitis | 1 | 2012 | 128 | 0.090 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1562 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 185 | 0.090 |
Why?
| | Organ Specificity | 1 | 2011 | 290 | 0.090 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2012 | 131 | 0.090 |
Why?
| | HLA Antigens | 2 | 2022 | 234 | 0.090 |
Why?
| | Male | 12 | 2024 | 63045 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2020 | 4874 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1827 | 0.080 |
Why?
| | Evidence-Based Medicine | 2 | 2024 | 712 | 0.080 |
Why?
| | Recurrence | 2 | 2024 | 1004 | 0.070 |
Why?
| | Hyperglycemia | 1 | 2012 | 326 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2011 | 420 | 0.070 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5371 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2016 | 1923 | 0.070 |
Why?
| | Combined Modality Therapy | 2 | 2020 | 1201 | 0.070 |
Why?
| | Patient Care Team | 1 | 2012 | 598 | 0.070 |
Why?
| | Still's Disease, Adult-Onset | 1 | 2024 | 5 | 0.060 |
Why?
| | Antiphospholipid Syndrome | 1 | 2024 | 37 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2016 | 2135 | 0.060 |
Why?
| | Infant, Newborn | 3 | 2019 | 5740 | 0.050 |
Why?
| | Vincristine | 1 | 2023 | 109 | 0.050 |
Why?
| | Animals | 4 | 2023 | 34647 | 0.050 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2022 | 48 | 0.050 |
Why?
| | Chromosome Inversion | 1 | 2022 | 17 | 0.050 |
Why?
| | Sirolimus | 1 | 2023 | 190 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2022 | 62 | 0.050 |
Why?
| | Antibodies, Neutralizing | 1 | 2024 | 264 | 0.050 |
Why?
| | Fetal Hemoglobin | 1 | 2021 | 6 | 0.050 |
Why?
| | Telomere | 1 | 2024 | 227 | 0.050 |
Why?
| | Liver Diseases | 1 | 2024 | 287 | 0.050 |
Why?
| | Eukaryotic Initiation Factors | 1 | 2021 | 10 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2022 | 196 | 0.050 |
Why?
| | Mice | 2 | 2022 | 16620 | 0.040 |
Why?
| | Venous Thromboembolism | 1 | 2024 | 283 | 0.040 |
Why?
| | Horses | 1 | 2021 | 106 | 0.040 |
Why?
| | North America | 1 | 2021 | 290 | 0.040 |
Why?
| | Unrelated Donors | 1 | 2020 | 36 | 0.040 |
Why?
| | Middle Aged | 4 | 2024 | 30923 | 0.040 |
Why?
| | Zebrafish Proteins | 1 | 2023 | 269 | 0.040 |
Why?
| | Bone Marrow | 1 | 2021 | 267 | 0.040 |
Why?
| | Anticoagulants | 1 | 2024 | 634 | 0.040 |
Why?
| | Tacrolimus | 1 | 2021 | 140 | 0.040 |
Why?
| | Ribosomes | 1 | 2021 | 164 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 842 | 0.040 |
Why?
| | Genetic Variation | 1 | 2024 | 935 | 0.040 |
Why?
| | Genotype | 1 | 2024 | 1830 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2719 | 0.040 |
Why?
| | Abdominal Cavity | 1 | 2018 | 5 | 0.040 |
Why?
| | Extravasation of Diagnostic and Therapeutic Materials | 1 | 2018 | 18 | 0.040 |
Why?
| | Phosphorylation | 1 | 2023 | 1686 | 0.040 |
Why?
| | Endothelial Cells | 1 | 2023 | 703 | 0.040 |
Why?
| | Ultrasonography, Interventional | 1 | 2018 | 128 | 0.040 |
Why?
| | Diagnosis, Differential | 1 | 2021 | 1412 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2024 | 2064 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2021 | 508 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2020 | 863 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2024 | 1490 | 0.030 |
Why?
| | Emulsions | 1 | 2016 | 45 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2024 | 2269 | 0.030 |
Why?
| | Mutation | 2 | 2021 | 3696 | 0.030 |
Why?
| | Pilot Projects | 1 | 2020 | 1568 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1423 | 0.030 |
Why?
| | United States | 2 | 2024 | 13840 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1027 | 0.030 |
Why?
| | Base Sequence | 1 | 2016 | 2137 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7069 | 0.020 |
Why?
| | Cohort Studies | 1 | 2022 | 5402 | 0.020 |
Why?
| | Uroporphyrinogen III Synthetase | 1 | 2011 | 1 | 0.020 |
Why?
| | Photosensitivity Disorders | 1 | 2011 | 8 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4399 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2741 | 0.020 |
Why?
| | Homozygote | 1 | 2011 | 193 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2011 | 301 | 0.020 |
Why?
| | Lung Injury | 1 | 2011 | 199 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3387 | 0.020 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1749 | 0.010 |
Why?
|
|
Nakano's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|